Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2004

View Archived Issues

Prous Science announces publication of a comprehensive review on sleep apnea

Takeda presents metastin derivatives for cancer therapy and other uses

New monoamine reuptake inhibitors developed at NeuroSearch

Novel chemokine CCR3 modulators and their use described by Boehringer Ingelheim

Two series of PTP inhibitors presented by TransTech researchers

Novel ALK4/ALK5 inhibitors discovered at Biogen Idec

New androgen receptor antagonists in early development at Pfizer

New Nurr1 activators with potential utility in PD therapy

New p38 MAP kinase inhibitors and their use claimed by Pfizer

Novo Nordisk updates program progress

Canadian approval for Lipitor to lower risk of heart attack

E.U. regulators to review long-term cardiovascular safety data for COX-2 inhibitors

Clinical investigators meeting endorses phase II ThromboView study

Transition Therapeutics sells Stem Cell Therapeutics to Neurogenesis Biotech

Takeda signs agreement to market Tavocept in U.S. and Canada

European approval sought for Surfaxin

Phase II study set to open this month evaluating Zyflo for acne

Small-molecule GSK-3 inhibitor stimulates bone formation in vitro and in vivo

Synthetic peptide promotes fracture healing in mouse model

Combination therapy overcomes resistance of prostate cancer cells to apoptosis

Epothilone derivative promising in human gliomas and drug-resistant melanomas

PI3K antagonist enhances radiation-induced vascular destruction in tumors

Good safety profile of anidulafungin in patients with invasive candidiasis

Clinical trials confirm the antifungal efficacy and safety of posaconazole

Liposomal-encapsulated paclitaxel well tolerated in prostate cancer patients

Development of mycobacterial cell wall-DNA complex advances

Beta-blocking drugs reduce risk of fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...